Form 4: Intra-Cellular Therapies Director Exercises Options and Sells Shares

Director Robert L. Van Nostrand exercised stock options and sold shares of Intra-Cellular Therapies, Inc. on February 27, 2024.

Summary

• On February 27, 2024, Robert L. Van Nostrand, a director of Intra-Cellular Therapies, Inc. (ITCI), exercised stock options to acquire 20,000 shares of common stock at a price of $18.56 per share.
• Following the exercise of the options, Van Nostrand sold 9,651 shares at a weighted average price of $72.71 and 10,349 shares at a weighted average price of $73.14.
• After these transactions, Van Nostrand directly owns 9,611 shares of Intra-Cellular Therapies, Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring these filings can provide insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although it is a common practice.
• The transactions have a minimal impact on employees, customers, suppliers, and creditors.

Key Dates